Stockreport

Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF SAN DIEGO, March 17, 2026 BUSINESS WIRE )--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, tod [Read more]